1
Wayne R Gombotz, Michael S Healy, Larry R Brown: Very low temperature casting of controlled release microspheres. Enzytech, Kilpatrick & Cody, May 28, 1991: US05019400 (302 worldwide citation)

A process for preparing microspheres using very cold temperatures to freeze polymer-biologically active agent mixtures into polymeric microspheres with very high retention of biological activity and material. Polymer is dissolved in a solvent together with an active agent that can be either dissolve ...


2
Jeffrey L Cleland, Ming Yang, John G Bauman, Nu Hoang, Emmett Cunningham: Compounds and compositions for the treatment of ocular disorders. Graybug Vision, Knowles Intellectual Property Strategies, November 7, 2017: US09808531 (3 worldwide citation)

The disclosure describes prodrugs and derivatives of prostaglandins, carbonic anhydrase inhibitors, kinase inhibitors, beta-adrenergic receptor antagonists and other drugs, as well as controlled delivery formulations containing such prodrugs and derivatives, for the treatment of ocular disorders.


3
Gombotz Wayne R, Healy Michael S, Brown Larry R: Very low temperature casting of controlled release microspheres. Enzytech, PABST Patrea L, November 15, 1990: WO/1990/013780 (2 worldwide citation)

A process for preparing microspheres using very cold temperatures to freeze polymer-biologically active agent mixtures into polymeric microspheres with very high retention of biological activity and material. Polymer is dissolved in a solvent together with an active agent that can be either dissolve ...


4
Jeffrey L Cleland, Ming Yang, John G Bauman, Nu Hoang, Emmett Cunningham: Compounds and compositions for the treatment of ocular disorders. Graybug Vision, Knowles Intellectual Property Strategies, May 1, 2018: US09956302 (1 worldwide citation)

The disclosure describes prodrugs and derivatives of prostaglandins, carbonic anhydrase inhibitors, kinase inhibitors, beta-adrenergic receptor antagonists and other drugs, as well as controlled delivery formulations containing such prodrugs and derivatives, for the treatment of ocular disorders.


5
Keith P Johnston, Joshua Engstrom, Robert O Williams III: Formation of stable submicron peptide or protein particles by thin film freezing. BOARD OF REGENTS THE UNIVERSITY OF TEXAS, Anson M Nomura, Mintz Levin Cohn Ferris Glovsky and Popeo P C, April 18, 2017: US09622974

The present invention includes compositions and methods for preparing micron-sized or submicron-sized particles by dissolving a water soluble effective ingredient in one or more solvents; spraying or dripping droplets solvent such that the effective ingredient is exposed to a vapor-liquid interface ...


6
Gombotz Wayne R, Healy Michael S, Brown Larry R: Moulage a tres basses temperatures de microspheres a liberation controlee, Very low temperature casting of controlled release microspheres. Alkermes Controlled Therapeutics, BERESKIN & PARR, November 2, 1990: CA2030550

VERY LOW TEMPERATURE CASTING OFCONTROLLED RELEASE MICROSPHERES Abstract of the Invention A process for preparing microspheres using very coldtemperatures to freeze polymer-biologically active agent mixtures intopolymeric microspheres with very high retention of biological activityand material. Polym ...


7

8
Phosphonate Compounds for Treatment of Medical Disorders. Achillion Pharmaceuticals, March 2, 2017: US20170057983-A1

Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is a phosphonate substituent (R32) are provided. The inhibitors described herein target Factor D ...


9
Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Medical Disorders. Achillion Pharmaceuticals, March 9, 2017: US20170066783-A1

Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an aryl, heteroaryl or heterocycle (R32) are provided. The inhibitors of Factor D described he ...


10
Amide Compounds for Treatment of Medical Disorders. Achillion Pharmaceuticals, March 2, 2017: US20170057950-A1

Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an amide substituent (R32) are provided. The inhibitors described herein target Factor D and i ...